M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,742 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,201 of 1,595 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,692 total, page 31 of 54
Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention
NCT02422329
Ultraviolet (UV) Photography in Adolescents
NCT02426853
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT02399917
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
NCT02269085
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
NCT02282345
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
NCT02311998
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
NCT02389751
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
NCT02397720
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
NCT02225405
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
NCT02392637
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
NCT02321540
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
NCT02302846
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
NCT02271711
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
NCT02225574
Cordotomy for Refractory Cancer Pain
NCT02345629
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
NCT02280525
Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
NCT02210065
PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
NCT02286713
Metformin in Non Small Cell Lung Cancer (NSCLC)
NCT02285855
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
NCT02302833
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
NCT02257138
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
NCT02366130
Denosumab for Breast Cancer With Bone Mets
NCT01952054
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
NCT02196857
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
NCT02295956
Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease
NCT02378701
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
NCT01740557
Mindfulness Based Couples Therapy
NCT02349217
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT02027935
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02199184
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
NCT02267278
A Culturally Sensitive Social Support Intervention
NCT02946697
Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study
NCT02302859
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
NCT02098161
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
NCT01924169
ICU Triage Practices in a Cancer Hospital
NCT03401411
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
NCT02126553
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
NCT02131597
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
NCT02292368
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
NCT02138929
Rational Therapeutics Based on Matched Tumor and Normal Tissue
NCT02272595
Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures
NCT02255773
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
NCT02135874
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
NCT02140021
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
NCT02269280
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
NCT02130453
Yoga Program for Lung Cancer Patients and Caregivers
NCT02196844
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
NCT02225496
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
NCT02135484
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
NCT02089230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
M.D. Anderson Cancer Center: open-pipeline peers nationwide
Peers matched on 2,692 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
M.D. Anderson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,692 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- National Cancer Institute (NCI) · 3,257 trials · 10% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 20% open enrollment (± trial volume)
- The University of Texas Health Science Center at San Antonio · 20% recruiting · 378 trials
- University of Georgia · 20% recruiting · 59 trials
- University of Houston · 20% recruiting · 64 trials
- Florida International University · 20% recruiting · 89 trials
Related
What to do with this M.D. Anderson Cancer Center page
2,692 registered trials is a research-attention snapshot, not an endorsement of M.D. Anderson Cancer Center or any single study.
- 549 of M.D. Anderson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hematopoietic and Lymphoid Cell Neoplasm is the condition M.D. Anderson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematopoietic and Lymphoid Cell Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. M.D. Anderson Cancer Center pipeline card: 2,692 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.